[1]
|
Loibl, S., Poortmans, P., Morrow, M., Denkert, C. and Curigliano, G. (2021) Breast Cancer. The Lancet, 397, 1750-1769. https://doi.org/10.1016/s0140-6736(20)32381-3
|
[2]
|
Li, J., Shao, Z., Xu, B., Jiang, Z., Cui, S., Zhang, J., et al. (2018) Use of Trastuzumab as an Adjuvant/Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer in China. Medicine, 97, e10350. https://doi.org/10.1097/md.0000000000010350
|
[3]
|
Xu, B., Li, W., Zhang, Q., Li, Q., Wang, X., Li, H., et al. (2022) Pertuzumab, Trastuzumab, and Docetaxel for Chinese Patients with Previously Untreated HER2-Positive Locally Recurrent or Metastatic Breast Cancer (PUFFIN): Final Analysis of a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. Breast Cancer Research and Treatment, 197, 503-513. https://doi.org/10.1007/s10549-022-06775-1
|
[4]
|
Ma, F., Yan, M., Li, W., Ouyang, Q., Tong, Z., Teng, Y., et al. (2023) Pyrotinib versus Placebo in Combination with Trastuzumab and Docetaxel as First Line Treatment in Patients with HER2 Positive Metastatic Breast Cancer (PHILA): Randomised, Double Blind, Multicentre, Phase 3 Trial. BMJ, 383, e076065. https://doi.org/10.1136/bmj-2023-076065
|
[5]
|
Wang, B., You, S., Xie, Y., et al. (2023) 427P Pyrotinib Plus Trastuzumab versus Pertuzumab Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study. Annals of Oncology, 34, S361-S362. https://doi.org/10.1016/j.annonc.2023.09.603
|
[6]
|
Miles, D., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Campone, M., et al. (2021) Final Results from the Peruse Study of First-Line Pertuzumab Plus Trastuzumab Plus a Taxane for HER2-Positive Locally Recurrent or Metastatic Breast Cancer, with a Multivariable Approach to Guide Prognostication. Annals of Oncology, 32, 1245-1255. https://doi.org/10.1016/j.annonc.2021.06.024
|
[7]
|
Zheng, Y., Cao, W., Shao, X., Shi, Y., Cai, L., Chen, W., et al. (2023) Pyrotinib Plus Docetaxel as First-Line Treatment for HER2-Positive Metastatic Breast Cancer: The PANDORA Phase II Trial. Nature Communications, 14, Article No. 8314. https://doi.org/10.1038/s41467-023-44140-y
|
[8]
|
Nader-Marta, G., Martins-Branco, D. and de Azambuja, E. (2022) How We Treat Patients with Metastatic HER2-Positive Breast Cancer. ESMO Open, 7, 100343. https://doi.org/10.1016/j.esmoop.2021.100343
|
[9]
|
Lin, N.U., Murthy, R.K., Abramson, V., Anders, C., Bachelot, T., Bedard, P.L., et al. (2023) Tucatinib vs Placebo, Both in Combination with Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients with Brain Metastases. JAMA Oncology, 9, 197-205. https://doi.org/10.1001/jamaoncol.2022.5610
|
[10]
|
Yan, M., Bian, L., Hu, X., Zhang, Q., Ouyang, Q., Feng, J., et al. (2020) Pyrotinib Plus Capecitabine for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer After Trastuzumab and Taxanes (PHENIX): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Translational Breast Cancer Research, 1, 13. https://doi.org/10.21037/tbcr-20-25
|
[11]
|
Yan, M., Ouyang, Q., Sun, T., Niu, L., Yang, J., Li, L., et al. (2021) Pyrotinib Plus Capecitabine for HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases (PERMEATE): A Multicenter, Single-Arm Phase II Study. Journal of Clinical Oncology, 39, 1037-1037. https://doi.org/10.1200/jco.2021.39.15_suppl.1037
|
[12]
|
Hua, X., Bi, X., Zhao, J., Shi, Y., Lin, Y., Wu, Z., et al. (2021) Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-Line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clinical Cancer Research, 28, 637-645. https://doi.org/10.1158/1078-0432.ccr-21-3435
|
[13]
|
Arpino, G., de la Haba Rodríguez, J., Ferrero, J., De Placido, S., Osborne, C.K., et al. (2023) Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. Clinical Cancer Research, 29, 1468-1476. https://doi.org/10.1158/1078-0432.ccr-22-1092
|
[14]
|
Tolaney, S.M., Barroso-Sousa, R., Jiang, Z., Park, Y.H., Rimawi, M., Saura Manich, C., et al. (2021) 328TiP Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or Without Pertuzumab vs a Taxane, Trastuzumab and Pertuzumab in First-Line (1L), Human Epidermal Growth Factor Receptor 2-positive (HER2 ) Metastatic Breast Cancer (mBC): DESTINY-Breast09. Annals of Oncology, 32, S507-S508. https://doi.org/10.1016/j.annonc.2021.08.611
|
[15]
|
Kulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., et al. (2020) Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. Molecular Cancer Therapeutics, 19, 976-987. https://doi.org/10.1158/1535-7163.mct-19-0873
|
[16]
|
Hamilton, E.P., Martin, M., O’Sullivan, C.C., Curigliano, G., Sohn, J., Tsurutani, J., et al. (2023) HER2CLIMB-05: Phase 3 Study of Tucatinib or Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for HER2 Metastatic Breast Cancer. Journal of Clinical Oncology, 41, TPS1115-TPS1115. https://doi.org/10.1200/jco.2023.41.16_suppl.tps1115
|
[17]
|
Wei, H., Cai, H., Jin, Y., Wang, P., Zhang, Q., Lin, Y., et al. (2017) Structural Basis of a Novel Heterodimeric Fc for Bispecific Antibody Production. Oncotarget, 8, 51037-51049. https://doi.org/10.18632/oncotarget.17558
|
[18]
|
Park, Y.H., Ahn, H.K., Kim, J., Ahn, J.S., Im, Y., Kim, S., et al. (2020) First-in-Human Phase I Study of ALT-P7, a HER2-Targeting Antibody-Drug Conjugate in Patients with HER2-Positive Advanced Breast Cancer. Journal of Clinical Oncology, 38, 3551-3551. https://doi.org/10.1200/jco.2020.38.15_suppl.3551
|
[19]
|
Emens, L.A., Esteva, F.J., Beresford, M., Saura, C., De Laurentiis, M., Kim, S., et al. (2020) Trastuzumab Emtansine plus Atezolizumab versus Trastuzumab Emtansine Plus Placebo in Previously Treated, HER2-Positive Advanced Breast Cancer (KATE2): A Phase 2, Multicentre, Randomised, Double-Blind Trial. The Lancet Oncology, 21, 1283-1295. https://doi.org/10.1016/s1470-2045(20)30465-4
|